Quick Reference
Code: F33 (with 4th and 5th character specifications)
Diagnosis: Major Depressive Disorder, Recurrent
Category: Mood (Affective) Disorders
Billing Status: Active code for reimbursement (requires 4th character)
DSM-5 Equivalent: 296.3x (Major Depressive Disorder, Recurrent)
Common Comorbidities: Anxiety Disorders, Substance Use Disorders, Personality Disorders, Chronic Pain, Cardiovascular Disease
Clinical Description
Major Depressive Disorder, Recurrent is characterized by two or more major depressive episodes separated by at least 2 months of remission. Each episode involves persistent depressed mood and/or loss of interest or pleasure, accompanied by additional symptoms that cause clinically significant distress or functional impairment.
ICD-10 Coding Specifications
F33.0 - Recurrent depressive disorder, current episode mild
F33.1 - Recurrent depressive disorder, current episode moderate
F33.2 - Recurrent depressive disorder, current episode severe without psychotic features
F33.3 - Recurrent depressive disorder, current episode severe with psychotic features
F33.4 - Recurrent depressive disorder, currently in remission
F33.8 - Other recurrent depressive disorders
F33.9 - Recurrent depressive disorder, unspecified
Diagnostic Criteria
For Major Depressive Episode:
Five or more of the following symptoms present during the same 2-week period (at least one must be depressed mood or loss of interest/pleasure):
Depressed mood most of the day, nearly every day
Markedly diminished interest or pleasure in activities
Significant weight loss/gain or appetite changes
Insomnia or hypersomnia nearly every day
Psychomotor agitation or retardation
Fatigue or loss of energy nearly every day
Feelings of worthlessness or excessive/inappropriate guilt
Diminished ability to think/concentrate or indecisiveness
Recurrent thoughts of death or suicidal ideation
For Recurrent Specification:
History of at least one previous major depressive episode
Current episode meets criteria for major depressive episode
Episodes separated by at least 2 consecutive months without significant mood symptoms
Severity Specifiers
Severity | Criteria | Functional Impact |
Mild | Few symptoms beyond minimum required; minor functional impairment | Able to function with effort |
Moderate | Symptoms/functional impairment between mild and severe | Significant functional difficulties |
Severe | Most symptoms present; marked functional impairment | Substantial impairment in most areas |
With Psychotic Features | Delusions or hallucinations present | Severe impairment with reality testing issues |
Differential Diagnosis
Condition | Distinguishing Features | ICD-10 Code |
Bipolar I Disorder | History of manic episodes | F31.x |
Bipolar II Disorder | History of hypomanic episodes | F31.81 |
Persistent Depressive Disorder | Chronic depression lasting 2+ years | F34.1 |
Adjustment Disorder with Depressed Mood | Clear stressor, symptoms within 6 months | F43.21 |
Substance-Induced Mood Disorder | Temporal relationship with substance use | F10-F19 |
Medical Condition-Related | Due to physiological effects of medical condition | F06.3x |
Bereavement | Normal grief response (though can co-occur). Must not include acute safety risks or persistent decline in function. | Z63.4 |
Transdiagnostic Considerations
MDD is part of the Internalizing disorders spectrum, sharing common symptoms and treatments with anxiety disorders and trauma-related conditions. Comorbidity rates are high, and treatment approaches often need to address multiple conditions simultaneously.
Assessment Tools
Validated Screening & Assessment Instruments
Instrument | Description | Scoring |
9-item self-report depression screener | 0-4: Minimal 5-9: Mild 10-14: Moderate 15-19: Moderately Severe 20-27: Severe | |
21-item self-report measure | 0-13: Minimal 14-19: Mild 20-28: Moderate 29-63: Severe | |
Clinician-administered, 17 or 21-item scale | 0-7: Normal 8-16: Mild 17-23: Moderate ≥24: Severe | |
10-item clinician-rated scale | 0-6: Normal 7-19: Mild 20-34: Moderate 35-60: Severe | |
15 or 30-item yes/no format for older adults | 15-item: 0-4: Normal 5-8: Mild 9-11: Moderate1 2-15: Severe | |
10-item scale for perinatal depression | Score ≥10 indicates possible depression Score ≥13 indicates likely depression |
Treatment Approaches
Evidence-Based Psychotherapy Options
Psychotherapy is a cornerstone of depression treatment, with multiple approaches showing strong efficacy. The choice of therapy should be individualized based on patient preferences, symptom profile, and treatment history.
Approach | Level of Evidence | Key Components | Typical Duration |
Cognitive Behavioral Therapy (CBT) | Strong | Cognitive restructuring, behavioral activation, relapse prevention | 16-20 sessions |
Interpersonal Therapy (IPT) | Strong | Focus on interpersonal relationships, grief, role transitions | 12-16 sessions |
Behavioral Activation (BA) | Strong | Activity scheduling, mood monitoring, values-based action | 12-16 sessions |
Psychodynamic Therapy | Moderate | Insight-oriented, transference work, unconscious patterns | 16-30 sessions |
Dialectical Behavior Therapy (DBT) | Moderate | Mindfulness, distress tolerance, emotion regulation | 12-24 sessions |
Acceptance and Commitment Therapy (ACT) | Moderate | Psychological flexibility, values clarification, mindfulness | 12-16 sessions |
Evidence-Based Medication Options
Antidepressant medications are highly effective for moderate to severe depression. Treatment selection should consider symptom profile, side effect tolerance, drug interactions, and patient preferences.
Medication Class | First-Line Options | Starting Dose | Target Dose | Notes |
SSRIs | Sertraline Escitalopram Fluoxetine Citalopram | 25-50 mg/day 5-10 mg/day 10-20 mg/day 10-20 mg/day | 50-200 mg/day 10-20 mg/day 20-80 mg/day 20-40 mg/day | Generally well-tolerated, sexual side effects common |
SNRIs | Venlafaxine XR Duloxetine Desvenlafaxine | 37.5-75 mg/day 30-60 mg/day 50 mg/day | 75-300 mg/day 60-120 mg/day 50-100 mg/day | Monitor blood pressure, discontinuation syndrome |
Atypical Antidepressants | Bupropion XL Mirtazapine Vortioxetine | 150 mg/day 15 mg/day 5-10 mg/day | 300-450 mg/day15-45 mg/day10-20 mg/day | Bupropion: seizure risk, weight loss Mirtazapine: sedation, weight gain |
Tricyclics | Nortriptyline Amitriptyline | 25 mg/day 25 mg/day | 75-150 mg/day75-300 mg/day | Cardiac monitoring, anticholinergic effects |
Treatment-Resistant Depression Options
Intervention | Evidence Level | Considerations |
Medication Augmentation | Strong | Lithium, thyroid hormone, antipsychotics |
Combination Therapy | Strong | Two antidepressants with different mechanisms |
Electroconvulsive Therapy (ECT) | Strong | Most effective for severe, psychotic, or catatonic depression |
Transcranial Magnetic Stimulation (TMS) | Moderate | FDA-approved for treatment-resistant depression |
Ketamine/Esketamine | Moderate | Rapid-acting, FDA-approved for treatment-resistant depression |
Vagus Nerve Stimulation (VNS) | Emerging | For chronic, treatment-resistant cases |
Integrative Treatment Considerations
Exercise: Moderate aerobic exercise (30+ minutes, 3-5 times/week) shows efficacy comparable to medication
Sleep interventions: CBT for insomnia, sleep hygiene, addressing sleep disorders
Nutritional factors: Mediterranean diet, omega-3 fatty acids, vitamin D supplementation
Light therapy: Particularly effective for seasonal patterns
Mindfulness-based interventions: MBSR, MBCT for relapse prevention
Social support: Group therapy, peer support, family involvement
Addressing Common Treatment Challenges
Challenge | Strategies |
Medication non-adherence | Psychoeducation, simplified dosing, side effect management |
Suicidal ideation | Safety planning, crisis contacts, family involvement |
Cognitive symptoms | Cognitive rehabilitation, medication optimization |
Chronic pain comorbidity | Integrated pain management, SNRIs, tricyclics |
Substance use comorbidity | Integrated treatment, motivational interviewing |
Antidepressant resistance | Medication augmentation, combination therapy, ECT |
Documentation, Coding, and Reimbursement
ICD-10 Coding Tips
F33 requires a 4th character to specify current episode severity
5th character may be used for additional specifications (e.g., F33.10 for mild episode without somatic syndrome)
Document episode count and duration of remission periods
Specify psychotic features when present (F33.3)
Use F33.4 for patients currently in remission
Can be used as primary or secondary diagnosis
Medical Necessity Documentation Language
Example statements to support medical necessity:
"Patient exhibits significant functional impairment in [specific domains] as evidenced by [specific examples]"
"Current major depressive episode represents [#] recurrence, with previous episodes occurring in [timeframe]"
"PHQ-9 score of [X] indicates [severity level] depression requiring professional intervention"
"Patient reports [specific symptoms] occurring daily for [duration] weeks"
"Suicidal ideation present with [frequency/intensity] requiring immediate intervention"
Other Documentation Requirements for Reimbursement
Documented evidence of at least 5 depressive symptoms
Duration criteria (2+ weeks) explicitly stated
Previous episode history documented
Functional impairment specified with examples
Suicide risk assessment documented
Differential diagnosis considered and ruled out
Treatment plan with specific, measurable goals
Specific Payer Considerations
Payer | Typical Reimbursement | Authorization Requirements | Session Limits |
Medicare | Covered under Part B | No prior auth for outpatient | No specific limit |
Medicaid | Varies by state | Often requires auth after 10-12 sessions | Varies by state |
BCBS | Covered | May require auth after 12-16 sessions | Varies by plan |
Aetna | Covered | Some plans require auth | Often 26 sessions/year |
UnitedHealthcare | Covered | Some plans require auth | Varies by plan |
Client Education Resources
Handouts for Clients
Digital Resources
Recommended Apps:
Moodtools: CBT-based depression management
Sanvello: Mood tracking and coping skills
Headspace: Meditation and mindfulness
Daylio: Mood and activity tracking
Online Communities:
NAMI (national alliance on mental illness)
Depression and Bipolar Support Alliance (DBSA) online support groups
Psychoeducational Talking Points
The neurobiological basis of depression: Depression involves changes in brain neurotransmitters (serotonin, norepinephrine, dopamine) and neural circuits, particularly those involved in mood regulation, reward processing, and stress response. These biological changes explain why depression isn't simply "feeling sad" but involves physical symptoms like fatigue, sleep disturbances, and concentration difficulties. Understanding the brain basis helps reduce self-blame and stigma while supporting the rationale for both medication and therapy, as treatments work by helping restore healthy brain function through different but complementary mechanisms.
The relationship between thoughts, mood, and behavior: Depression creates a negative cycle where pessimistic thoughts fuel depressed mood, which leads to withdrawal and inactivity, which then generates more negative thoughts about being "lazy" or "worthless." This cycle is self-reinforcing because depression affects our ability to think clearly and remember positive experiences. Breaking this cycle requires intervening at multiple points: challenging negative thought patterns, gradually increasing meaningful activities, and improving physical health through sleep, exercise, and nutrition.
Depression as a treatable medical condition: Depression is a legitimate medical illness with biological, psychological, and social components. Like diabetes or heart disease, it requires proper treatment and management. Recovery is possible with appropriate treatment, though it may take time to find the right combination of approaches. The recurrent nature of depression means that learning long-term management strategies is crucial, similar to managing other chronic conditions.
The importance of behavioral activation: When depressed, people naturally withdraw from activities, which temporarily reduces stress but ultimately worsens depression by eliminating sources of pleasure, accomplishment, and social connection. Behavioral activation involves gradually re-engaging with meaningful activities, even when motivation is low. Starting with small, achievable tasks helps rebuild confidence and energy. The key is that behavior change often precedes mood improvement, so patients shouldn't wait to "feel better" before becoming active.
Recognizing early warning signs and relapse prevention: Since depression is often recurrent, learning to identify personal early warning signs is crucial for preventing full episodes. These might include sleep changes, increased irritability, social withdrawal, or negative thinking patterns. Developing a relapse prevention plan includes maintaining healthy routines, staying connected with support systems, continuing beneficial activities, and seeking help promptly when warning signs appear. Many people benefit from "maintenance" therapy sessions to monitor symptoms and maintain coping skills.
Reference Materials and Further Reading
Clinical Practice Guidelines
American Psychological Association Clinical Practice Guidelines for Depression (2019)
National Institute for Health and Care Excellence (NICE) Depression Guidelines (2022)
Emerging Research
Precision medicine approaches for depression treatment selection
Chekroud AM, Bondar J, Delgadillo J, et al. The promise of machine learning in predicting treatment outcomes in psychiatry. World Psychiatry. 2021 Jun;20(2):154-170.
Digital therapeutics and smartphone-based interventions
Linardon J, Cuijpers P, Carlbring P, Messer M, Fuller-Tyszkiewicz M. The efficacy of app-supported smartphone interventions for mental health problems: a meta-analysis of randomized controlled trials. World Psychiatry. 2019 Oct;18(3):325-336.
Inflammation and depression: novel treatment targets
Köhler-Forsberg O, N Lydholm C, Hjorthøj C, et al. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of clinical trials. Acta Psychiatr Scand. 2019 Oct;140(4):266-281.
Personalized neurostimulation approaches
Siddiqi SH, Weigand A, Pascual-Leone A, Fox MD. Identification of personalized transcranial magnetic stimulation targets based on subgenual cingulate connectivity: An independent replication. Biol Psychiatry. 2021 Jan 15;89(2):e55-e57.
Specialized Books for Clinicians
"Cognitive Therapy of Depression" by Aaron T. Beck, A. John Rush, Brian F. Shaw, and Gary Emery
This seminal work established the foundation for cognitive therapy of depression and remains the gold standard reference. It provides detailed treatment protocols, case examples, and the theoretical framework for understanding depression from a cognitive perspective. Essential for any clinician using CBT approaches with depressed patients.
"Interpersonal Psychotherapy of Depression: A Brief, Focused, Specific Strategy" by Gerald L. Klerman and Myrna M. Weissman
The definitive guide to IPT, this book provides structured treatment protocols focusing on interpersonal relationships and their role in depression. It offers practical session-by-session guidance and is particularly valuable for clinicians treating depression with relationship and social functioning components.
"Behavioral Activation for Depression: A Clinician's Guide" by Christopher R. Martell, Sona Dimidjian, and Ruth Herman-Dunn
This comprehensive guide presents behavioral activation as a standalone treatment for depression. It provides detailed protocols, case examples, and practical strategies for helping clients re-engage with meaningful activities and break the cycle of depression and withdrawal.
"Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse" by Zindel V. Segal, J. Mark G. Williams, and John D. Teasdale
This book presents MBCT as an evidence-based approach for preventing depressive relapse. It provides detailed protocols combining mindfulness practices with cognitive therapy techniques, particularly valuable for clients with recurrent depression.
Last Updated: June 2025
About This Resource: This comprehensive guide was developed to support mental health professionals in providing evidence-based assessment and treatment for clients with Major Depressive Disorder. While efforts have been made to ensure accuracy, clinicians should refer to current DSM-5 and ICD-10 manuals for official diagnostic criteria and stay informed about evolving best practices.
